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Fourteen years after the discovery that mutations in Cu, Zn superoxide dismutase (SOD1) cause a subset of familial amyotrophic lateral
sclerosis (fALS), the mechanism by which mutant SOD1 exerts toxicity remains unknown. The two principle hypotheses are (a) oxidative
damage stemming from aberrant SOD1 redox chemistry, and (b) misfolding of the mutant protein. Here we review the structure and
function of wild-type SOD1, as well as the changes to the structure and function in mutant SOD1. The relative merits of the two
hypotheses are compared and a common unifying principle is outlined. Lastly, the potential for therapies targeting SOD1 misfolding is
discussed.
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Metalloprotein1. Introduction
Cu, Zn superoxide dismutase (SOD1) is a highly conserved
enzyme that is the primary cytoplasmic scavenger of superoxide
radical (O2
−). In 1992, Rosen et al. [1] discovered that the ALS1
gene is SOD1 and that mutations in this gene can cause
amyotrophic lateral sclerosis (ALS). SOD1 mutations are the
most common known cause of ALS, associated with 2–10% of
cases [2]; mutations in ALS2 (Alsin, a guanine nucleotide
exchange factor) [3], VAPB (vesicle associated membrane
protein B) [4] and ANG (angiogenin) [5] also account for a
small number of cases. Despite more than a decade since this
discovery and more than 1200 publications relating SOD1 and
ALS [6], the causal mechanism behind SOD1 mediated ALS
remains elusive. In recent years, a mechanism involving SOD1
misfolding has gained prominence; this review will focus on
SOD1 structure and function, normal SOD1 folding, and the
possible role for SOD1 misfolding in ALS. In each case, the
properties of the normal wild-type protein will be compared and
contrasted with those of the mutant protein.⁎ Corresponding author. Tel.: +1 416 581 7553; fax: +1 416 581 7562.
E-mail address: chakrab@uhnres.utoronto.ca (A. Chakrabartty).
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Superoxide (O2
−) is generated in a number of cellular
processes (for a review, [7]), including oxidative bursts from
immune cells (primarily neutrophils) and as a by-product of
normal respiration. In this case, co-enzyme Q (ubiquinone)
may reduce molecular oxygen, instead of complex I or
complex III, producing superoxide; this occurs in ∼1% of
electron transport events [7]. Superoxide can be produced, in
vitro, through reduction of oxygen in an electrolytic cell [8],
by pulse radiolysis [9], or enzymatically with xanthine and
xanthine oxidase [10]. The activity of xanthine oxidase on
xanthine produces superoxide as a byproduct of its enzymatic
activity, based on its ability to reduce cytochrome c in an
oxygen dependent and catalase independent manner. Cu, Zn
superoxide dismutase (known earlier as erythrocuprein) has
long been known as the major copper containing protein in
erythrocytes ([11], and refs therein), but its enzymatic
function was not discovered until 1969, when McCord and
Fridovich found that ‘erythrocuprein’ dismutes superoxide.
That is, it catalyzes the disproportionation reaction where the
first superoxide molecule is oxidized and the second molecule
is reduced, turning two molecules of superoxide into O2 and
Fig. 1. Structure of a SOD1 dimer (pdb code: 1SPD). The left subunit is shown
in stick representation for detail. Copper is coloured blue, zinc is coloured
lavender. Bridging His 63 is shown in red; the secondary bridge is shown His 46
(yellow)–Asp 124 (magenta)–His 71(yellow). The remaining metal binding
histidines are shown in cyan. The right subunit is shown as a cartoon ribbon to
illustrate the overall architecture of the SOD1 subunit. The beta barrel is shown
in gray, the metal binding loop in green and the electrostatic loop in blue.
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‘ping-pong’ mechanism [12]:
Here the copper is at the SOD1 active site. The superoxide
dismutase activity of erythrocuprein (and the major copper
containing protein in virtually all tissues) inhibits the reduction
of cytochrome c by extrinsically added superoxide or
superoxide produced in situ [8]. This reaction forms the basis
for the enzyme assay still commonly used today. In a related
assay, superoxide is generated by dissolved oxygen and the
radical generating system of riboflavin, UV light, and
tetramethylene diamine (TEMED), which produces a coloured
product upon reduction of nitroblue tetrazolium (NBT); SOD1
competes with NBT for the superoxide radical [10]. This assay
has been adapted to measure SOD1 activity in a native
eletrophoretic gel and, by its very nature, is free of interference
from competitive inhibition by cytochrome c oxidase present in
cell and tissue homogenates. A microplate assay for SOD1
activity is also available [13]. SOD1 mimetics have been used in
attempts to protect against the superoxide burst produced upon
reperfusion of an ischemic event [14], though these have
catalytic rate constants 2–4 orders of magnitude slower than the
authentic Cu, Zn superoxide dismutase [15].
3. SOD1 structure
Eukaryotic SOD1 is a stable homodimer where each subunit
is related to the other by an approximate C2 axis of rotation in
mammals and, strikingly, an exact (non-crystallographic) C2
axis of rotation in yeast [16]. This orients the active site of one
subunit on the opposite side of the molecule relative to the other
subunit. The dimer is held together primarily with hydrophobic
contacts, burying approximately 550 Å of hydrophobic surface
area in the interface of the two subunits [17]. Dimerization of
SOD1 reduces the solvent accessible surface area, greatly
increasing its stability [18]. SOD1 is also one of the most stable
proteins known. The fully metallated protein melts at 85–95 °C
(depending on buffer, e.g. [19]) and is enzymatically active in
8 M urea or 4 M guanidine–HCl [20]. E. coli SOD is highly
homologous to the mammalian enzyme, but is monomeric [21].
The active site of this enzyme was more easily denatured than
the mammalian, dimeric SOD1 and the E. coli protein as a
whole has a melting temperature 17.7 °C lower than the human
protein [21]. Several engineered monomeric SOD1s have been
created by mutating residues within the hydrophobic dimer
interface to charged residues [22]. These monomeric mutants
show disorder in the metal binding loop and the catalytically
important Arg 143[23] is also highly disordered. This disorder
results in a 10-fold loss in activity, but this can be abrogatedsomewhat by compensatory mutations that stabilize the active
site with hydrogen bonding [24]. Dimerization may also be
related to cooperative function of the two subunits [25], but this
has not been confirmed experimentally.
SOD1 is part of the immunoglobulin-fold family [26], of
which each monomer consists primarily of an eight-stranded
beta-barrel with two large loops, the so-called ‘electrostatic
loop’ and the ‘metal binding’ loop (Fig. 1) [17]. The
electrostatic loop (residues 122–143) has a number of charged
residues, but these are not likely catalytically important because
mutating four residues to uncharged residues actually increases
the catalytic rate constant. The ‘metal binding’ loop (residues
49–84) contains many of the residues necessary for binding of
the metals [27]. The topological and hydrogen bonding
connectivity of the strands within each SOD1 monomer is
reminiscent of the connectivity of lines found in ancient Greek
pottery, and is accordingly called the ‘Greek-key’ fold [28].
Because the N-terminus and C-terminus of SOD1 are adjacent,
it was possible to produce circular permutants of SOD1 by
connecting these and ‘cutting’ loops connecting other strands,
which creates a new N- and C- terminus. These permutants have
similar expression, stability and rates of catalysis of wild-type
SOD1[28]. Strands 1, 2, 3 and 6 are regular, with little twisting,
and are on the opposite face of the barrel from the active site.
Strands 4, 5, 7 and 8 are shorter and more twisted than the other
half of the barrel. Several ‘beta bulges’ in these strands
accommodate metal binding [17]. It has been hypothesized that
the two halves of the barrel are the product of primordial gene
duplication [29]. A conserved disulfide bond between residues
57 and 146 [amino acid numbering is for the human enzyme
throughout] greatly increases SOD1 stability [30]. Similar
disulfide bonds are present in other immunoglobulin fold
proteins [26].
Each SOD1 monomer also contains two metal ions, one
copper and one zinc, which play structural and catalytic roles in
the enzyme. The catalytic copper is bound by four histidines,
Fig. 2. Surface charges on SOD1 dimer (pdb code: 1SPD). The dimer is shown
with the same orientation as in Fig. 1. Positively charged areas are coloured blue,
negatively charged areas are coloured red. The active site positive charge
enhances electrostatic guidance of superoxide to the copper centre. Negative
charges dominate the remainder of the SOD1 dimer surface. Surface and
electrostatic calculations were carried out with Swiss PDB viewer (freely
available at http://www.expasy.org/spdbv/) [141] using the following para-
meters: dielectric constant (solvent) =80; use atomic partial charges; map
potential to surface; computation method: Coulomb; dielectric constant
(protein)=4; colour scale: red=− 1.800, white=0.000, blue =1.800.
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geometry in the oxidized (Cu(II) ) form and in a distorted
trigonal planar geometry, bound by His 46, 48 and 120 in the
reduced (Cu(I)) form [17]. There is also evidence for a fifth
water ligand for copper in the oxidized state [16]. A network of
hydrogen bonds may reduce negative effects of distorted
binding geometries of the two metals [17]. The zinc ion, which
is bound by His 63, 71, 80 and Asp 83 acting as a monodentate
ligand, is thought to play a structural role and act as a positive
charge sink. His 63 bridges the copper and zinc ions where its
delta-nitrogen is a zinc ligand and its epsilon-nitrogen is a
copper ligand. A secondary bridge exists where Asp 124
hydrogen bonds to both His 46 (a copper ligand) and His 71 (a
zinc ligand). Mutation of Asp124 to Asn (analagous to the ALS-
associated mutant D124V) precludes formation of this hydro-
gen bond, leading to a dramatic decrease in zinc binding affinity
[31]. This metal binding architecture, where the two metals are
bridged by a histidine side chain as well as by a secondary
linkage of hydrogen bonds, appears to be unique in metallo-
enzymes [17].
4. Mechanism of SOD1 activity
The standard reduction potential for the O2/O2
− couple is
−0.33 Vand for the O2−/ H2O2 couple is + 0.89 V [12]. Thus, any
redox-active metal with a reduction potential between these two
values can oxidize and reduce superoxide by catalyzing the
spontaneous transfer of an electron to the metal and to
superoxide in a subsequent step. The nominal reduction
potential of the Cu2+/Cu+ couple is + 0.16 V [32]. Verhagen
et al. measured the reduction potential of Cu2+-SOD1/Cu+-
SOD1 as + 0.12 Vat pH 7.5 in 0.2 M salt at 22 °C [33]. WhetherSOD1 actually catalyzes both reactions, or instead catalyzes
only the oxidation or reduction of superoxide and then is
restored to the active state with another redox agent is an issue
that was resolved only recently. In fact, SOD1 mimetics often
have only one of these activities. Liochev and Fridovich showed
that SOD1 can participate in a couple with ferrocyanide or
ferriccyanide, illustrating that the enzyme acts as both a
superoxide oxidase and a superoxide reductase [34].
The details of the enzymatic mechanism come from a
number of high-resolution X-ray crystal structures and NMR
data and lower resolution, but still important EXAFS and ESR
data. The active site is positively charged and makes up
approximately 11% of the total exposed surface [35], but the
rest of the surface is negatively charged (Fig. 2). This charge
gradient increases the equilibrium concentration of superoxide
near the active site channel, but the electric field gradients show
that superoxide would be repelled from the sides of the channel
itself. Based on the rate of diffusion of superoxide and SOD1,
the SOD1 catalytic rate constant of 2×109 M−1 s−1 is
approximately diffusion controlled once superoxide approaches
the SOD1 active site [36]. Increasing the positive charge at the
active site while preserving the hydrogen bonding network can
increase the rate of SOD1 catalytic activity by enhancing
electrostatic guidance [37]. The active site is also much more
evolutionarily conserved (86%) than the rest of the SOD1
sequence (41%). The catalytic importance of Arg 143 is thought
to stem from hydrogen bonding with the incoming superoxide
[35]. Arg 143 and Thr 137 also limit the size of anions incoming
to the copper-active site [16]. Based on EXAFS and ESR data
[38,39], the copper becomes tri-coordinated upon reduction to
Cu(I) and the bridging histidine no longer binds to copper. This
allows for relaxation of the otherwise unfavourable distortions
in the binding geometry of the zinc binding ligands [35] and
allows the histidine to become protonated, which is facilitated
by the increased acidity of this ligand by the zinc ion. This
proton is then abstracted from His 63 to the outgoing O2
2−.
Crystallization of SOD1 in the Cu(I) state also shows that the
histidine bridge is broken by a rotation of the imidazolate side
chain which moves the liganding nitrogen 0.66 Å away from the
copper ion [16]. Based on a number of crystal structures with
copper oxidized or reduced and with competitive inhibitors
bound, Hart et al. [16] proposed a mechanism for SOD1
activity. The first step of the reaction is binding of the
superoxide to the copper active site displacing the axial water
ligand. There is an inner sphere electron transfer (the electron is
transferred through a bond) to the copper and the oxygen
diffuses out. This causes a rearrangement to the trigonal bound
Cu(I) state, which is then oxidized by a second, non-covalently
bound, superoxide in an outer sphere (the electron is transferred
through space rather than through a bond) mechanism, regene-
rating the Cu(II) state (Fig. 3).
5. SOD1 folding and molecular dynamics
Understanding the dynamics of protein motion in addition to
the structure of a protein are important to understanding its
function and potential malfunction [40]. The dynamics can be
Fig. 3. Comparison of the SOD1 active site in the Cu(I) and Cu(II) states.
Copper is blue, zinc is gray. (A) The active site in oxidized SOD1 (Cu(II)) shows
copper liganded with four histidines, including the bridging histidine. (pdb code:
1SPD) (B) SOD1 active site in the reduced state (Cu(I)), where the active site
copper is no longer bound by the bridging histidine (pdb code: 1Q0E; note:
reduced bovine SOD1 is shown for clarity—the structure of reduced human
SOD1 shows double occupancy of the copper in the reduced site and the
oxidized site).
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simulations. Early molecular dynamics simulations of SOD1
dynamics (300 ps) revealed that there are instantaneous
asymmetric motions of the two SOD1 subunits through
essential dynamics analysis [25]. Motion in the beta-barrel of
one subunit influences the motion of the other subunit,
including re-organization of the electrostatic channel to enhance
the interaction with the substrate. In an experimental and
computational study on SOD1 from Photobacterium leiognathi,
Falconi et al. show that enhancement of the intersubunit
communication can increase the cooperativity of the enzyme
and increase the catalytic rate by approximately 2-fold when
introducing a V29G mutation [41]. The P. leiognathi SOD1
dimer interface, however, is oriented on a different face of the
monomer than is human SOD1, so the role of intersubunit
communication in the human protein has not yet been
substantiated experimentally. In a recent five nanosecond
molecular dynamics study, Khare et al. found that the
intersubunit communication is decreased in mutant SOD1
when the connectivity of amino acid residues was analyzed
using graph theoretic methods [42]. The groups of Banci and
Bertini have also studied the dynamics of SOD1 and mutantderivatives with NMR [43–47]. Using an engineered mono-
meric SOD1 derived from the human sequence, they observed
NMR line width broadening, indicative or greater mobility, in
loops 4 and 6, which are close to the dimer interface. Perhaps
not surprising based on computational data, they also observe
greater mobility in the electrostatic loop, which is opposite the
dimer interface [47]. They also observe a decrease in enzyme
activity that is proportional to the width of the active site
channel formed from reorganization of this electrostatic loop;
sterically restricting access to the active site reduced the enzyme
activity. There are also large differences in the backbone
dynamics of the monomeric mutant SOD1 compared to the
wild-type dimer, which is more rigid [44]. Engineered
monomeric SOD1 also shows a loss of hydrogen bonds at the
active site, especially with Asp 124, which serves as a
secondary bridge between the copper and zinc ions and is
necessary for reorganization of the zinc binding site [45]. When
the dynamic properties of G93A mutant SOD1 were probed
with NMR, similarities to the engineered monomer were found.
There was increased disorder in the loops and an increase in the
destabilization of residues necessary for blocking edge-strand
aggregation [48]. SOD1 mutations also destabilized the amino
acids at the ends of the beta-barrel in a computer simulation of
other fALS associated mutant SOD1s [42].
Studies into SOD1 folding have been limited because of the
intrinsic difficulties in studying the folding behaviour of a
protein that undergoes extensive post-translational maturation
steps and by the resulting complexity of the equilibrium of
various states of SOD1. The variables in these states include:
differing metallation status, whether the copper is oxidized or
reduced, the redox state of the disulfide bond, dimerization,
subunit communication and subunit asymmetry; each of these
need to be evaluated properly to understand the folding
behaviour of SOD1. Several groups have, however, attempted
to study the unfolding and refolding of SOD1 under fully
metallated or apo-conditions. The nature of the tryptophan
environment has been probed with fluorescence lifetime
measurements, where the lifetime is dependent on both
temperature and conformation [49]. Guanidine–HCl induced
denaturation produces sharp sigmoidal unfolding curves where
the midpoint is dependent upon proper metallation. However,
the width of the fluorescence lifetime distribution at the
transition midpoint, circular dichroism, analytical ultracentrifu-
gation and fluorescence anisotropy measurements revealed a
partially folded monomeric intermediate in the SOD1 unfolding
pathway [50,51]. There is also strong kinetic hysteresis in the
guanidine induced denaturation of SOD1 which reveals a
monomeric kinetic intermediate in addition to thermodynamic
intermediates observed earlier [52]. Thermal denaturation of
holo- and apo-wild-type SOD1 can be approximated as a two-
state unfolding process [53], suggesting that the folding
intermediates are unstable at higher temperatures. However,
fitting thermal denaturation of mutant apo-SOD1 is complicated
by competing aggregation reactions [53]. Thus, SOD1 folding is
either three-state (native/folded, intermediate, and unfolded) or
two-state (native/folded and unfolded), depending on the protein
concentration, temperature and the presence of mutations.
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SOD1 is subject to at least four post-translational maturation
steps in addition to N-terminal acetylation: copper insertion,
zinc insertion, dimerization and disulfide bond formation.
Failure or alteration of one or more of these processes could
result in a build up of immature SOD1 which will not be
properly folded since the native protein requires each of these
modifications to maintain its structure and stability. Thus, a
mutation in a gene that controls SOD1 post-translational
modification may mimic a SOD1 mutation in fALS by causing
improper folding of SOD1 (Fig. 4). In familial Alzheimer's
disease, mutations in APP itself or one of the presenilin genes
responsible for post-translational cleavage of the A-beta peptide
from APP can cause disease [54]. Since SOD1 mutations
account for only 20–25% of fALS [2], perhaps a gene involved
in the post-translational maturation of SOD1 accounts for some
fraction of the remainder.
O'Halloran and co-workers succinctly demonstrated that
intracellular copper and zinc levels are less than one free metal
ion per cell [55,56]. Copper is inserted into SOD1 in yeast cells
through the copper chaperone for SOD1 (CCS) [57]. CCS
consists of three domains: domains I and III are thought to be
necessary for copper insertion into SOD1, while domain II is
homologous to SOD1. SOD1 and CCS may form a heterodimer
during copper insertion using the same interface as that of
SOD1 homodimerization [58]; however, another model, where
a CCS homodimer and SOD1 homodimer dock in a hetero-
tetramer avoids the energetically unfavourable dissociation of
the SOD1 dimer [59]. It is unknown how CCS obtains copper
from outside the cell, but perhaps it acquires it from the copper
transporter Ctr [58]. Mammalian SOD1 can be activated in a
CCS-dependent or CCS-independent manner [60]. CCS-
independent activation relies on reduced glutathione. CCS-
independent activation of SOD1 can only take place in the
absence of two proline residues that are present in yeast SOD1.
Introduction of these prolines into human SOD1 renders it
completely dependent upon CCS in vivo for proper copper
insertion [61]. Insertion of copper into SOD1 from Caenor-Fig. 4. SOD1 undergoes extensive post-translational maturation. Mutations in genes
and function. The relevant genes are shown under each step.habditis elegans occurs exclusively through a CCS-independent
pathway [62].
The presence of an intramolecular (within each subunit)
disulfide bond in SOD1 is somewhat unexpected since it is
present at high concentration within the reducing environment
of the cytoplasm. The stability of SOD1 is dependent upon
proper disulfide bond formation [63]. The apo-disulfide-
reduced form shows a similar circular dichroism spectrum to
the oxidized form, but has an NMR HSQC spectrum similar to
the engineered SOD1 monomer and is also monomeric in size-
exclusion chromatography [63]. The monomeric, disulfide
reduced, apo-SOD1 also displays two-state folding behaviour
[64]. FALS associated mutant SOD1s are also more susceptible
to disulfide reduction than the wild-type protein [65]. CCS
appears to play an important role in the formation of the SOD1
disulfide bond. SOD1 activity is disulfide bond dependent and
CCS can activate the enzyme even in the presence of EDTA (a
Cu (II) chelator) and bathocuprein sulfate (a Cu (I) chelator)
[66]. Moreover, apo-CCS can also catalyze the formation of the
SOD1 disulfide bond, albeit slowly. Whether disulfide bond
formation precedes, is concomitant with copper insertion, or is a
product of fast auto-oxidation from SOD1 active site copper is
still unknown.
The mechanism of zinc insertion is unknown, but because
zinc concentrations are regulated with femtomolar sensitivity
[55,67], we speculate that there is a factor that inserts zinc
specifically into SOD1 or non-specifically into a number of
proteins, as opposed to acquiring it from a freely diffusible
pool or only loosely bound zinc. This may be one of the
metallotheineins, or another unknown protein or small molecule.
Whether dimerization occurs spontaneously, or requires a cha-
perone or some other factor is also unknown.
SOD1 is ubiquitously expressed, but is present in some
tissues at higher concentration than others [68]. Metabolic
labeling with 64Cu in mouse fibroblasts shows that the
concentration of apo-SOD1 is inversely proportional to
copper levels and that copper is rapidly incorporated into
both pre-formed apo-SOD1 and newly translated SOD1[69].
In addition, SOD1 may be inducible under conditions ofthat alter post-translational processing of SOD1 may also affect SOD1 stability
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inducible upon oxidative stress where protein synthesis is
inhibited [70]. The mechanism of oxygen induced transcrip-
tional activation of SOD1 and the control over differential
tissue expression of SOD1 are active areas of research.
7. Aberrant enzymatic activity of mutant SOD1
Superoxide associated toxicity has been associated with
longevity and disease [71]. Based on the tight genetic linkage
between some patients with fALS to a locus on chromosome
21q which contains the SOD1 gene and the putative role of
oxygen radicals in ageing and neurological diseases, Rosen et
al. investigated SOD1 as the causative gene in fALS [1]. Upon
conducting PCR on 2 of the 5 SOD1 exons, they found that
mutations in SOD1 were correlated with fALS. Familial ALS is
dominantly inherited; how a mutation in one of the copies of a
ubiquitously expressed gene causes a dominantly inherited
phenotype was, and remains, the major unanswered question.
Rosen et al. suggested that mutations might actually increase
SOD1 activity or have a dominant negative effect whereby the
mutant inactivates the wild-type protein in a heterodimer.
However, it was later shown that several (A4V, G37R, G41D,
G93C, I113T) mutant SOD1s have similar in vitro activity to
that of wild-type SOD1. Only G85R, a mutation close to the
metal binding site (see below) lacked activity [72]. This and
other metal binding region mutant SOD1s do not rescue the
SOD1−/− lysine auxotrophy phenotype in yeast [73]. Further-
more, mutant SOD1s do not have a dominant negative effect on
wild-type subunit function [74]. In addition to these in vitro
experiments, several lines of evidence from mouse genetic
studies point to a SOD1 gain-of-function mutation rather than a
loss of function. Mice expressing greater than normal levels of
mutant human SOD1 produced ALS-like motor neuron
pathology, despite the presence of normal endogenous mouse
SOD1[75,76]. This is also true of the G85R SOD1 mutant, even
when expressed to lower levels than that required to produce a
phenotype with the G93A and G37R SOD1 mutants [77].
Removing the mouse SOD1 gene did not produce a motor
neuron phenotype [78].
In addition to its superoxide dismutase activity, SOD1 also
has peroxidase activity, whereby it generates radicals from
hydrogen peroxide [79]. A4V and G93A mutant SOD1
increased the rate of hydroxyl radical formation as monitored
by the electron spin resonance change of the spin-trap 5,5′-
dimethyl-1-pyrroline N-oxide (DMPO) [80]. This change in
reactivity is attributed to a change in the mutant enzyme'sKm for
H2O2 [81,82]. Treatment of SOD1 with H2O2 also damages the
enzyme by oxidative modification of histidine to 2-oxo-histidine
[83]. This modification leads to copper release in the Cu (I) form
and subsequent inactivation of SOD1[84]. The oxidative
modifications of histidine also leads to damage of the zinc site,
which occurs much more rapidly than enzyme inactivation
through copper loss [85]. Bicarbonate protects SOD1 fromH2O2
induced inactivation; however, it also catalyzes the formation of
a carbonate anion radical, increasing the overall peroxidase
activity of SOD1[86]. Hydrogen peroxide first reduces the Cu(II) to Cu (I), as seen by the loss of the absorbance at 650 nm
from the Cu d–d* excitation, and then catalyzes the formation of
the carbonate anion radical, which may then diffuse and oxidize
various exogenous substrates [87]. Dissolved CO2 may also
react with H2O2 + SOD1, also increasing its peroxidase activity
[88]. The exact radical species being generated is highly
dependent upon solution conditions and whether the peroxidase
activity also occurs in vivo is unknown.
Superoxide also reacts in a near diffusion-limited reaction
with nitric oxide which produces peroxynitrite [89]. Peroxyni-
trite rapidly degrades under physiological conditions to produce
hydroxyl radical and nitrogen dioxide radical [90]. Wild-type
SOD1 can also react with peroxynitrite to produce a highly
reactive nitronium species, which can then nitrate tyrosine
residues. Mutant SOD1 could have greater nitrating activity
than the wild-type enzyme because of increased disorder in the
residues that mediate anion selectivity in the active site [91].
Mutations produce a partially metallated zinc-deficient form of
SOD1 [92] that promotes apoptosis in a nitric oxide dependent
manner in cultured motor neurons replete with growth factors,
whereas the holo-protein rescues cultures deprived of trophic
support [93]. That is, the holo-protein protects against oxidative
damage caused by trophic factor withdrawal, but the zinc-
deficient form produces enough oxidative stress that it causes
cell death in the absence of exogenous oxidative stress (from
trophic factor withdrawal). The complex interaction of nitric
oxide, superoxide, peroxynitrite, SOD1 and their targets,
however, makes it difficult to predict which species is the
most culpable and what the intracellular targets of modification
might be [94]. The ‘SOD1 oxidation/nitration’ hypothesis has
been tested in vivo. Cleveland and co-workers showed that
there is an increase in free, but not protein bound nitrotyrosine
in ALS [95]. Free nitrotyrosine is also sufficient to cause motor
neuron, but not astrocyte, apoptosis [96]. Aberrant reactivity of
mutant SOD1 with nitric oxide has also been linked to a
disruption of nitric oxide signaling. SOD1 catabolizes S-
nitrosothiol containing peptides [97], which depletes the overall
S-nitrosothiol content of various cellular components and
interferes with nitric oxide signaling [98].
Despite in vitro and in vivo evidence of aberrant copper
chemistry in fALS mutant SOD1 pathogenesis, the hypotheses
linking mutant SOD1 toxicity to copper mediated chemistry has
recently come into disfavour because of two key experiments.
First, copper is predominantly inserted into SOD1 by the copper
chaperone for SOD1 (CCS) in mammals [60] and exclusively in
yeast [56]. Crossing a mouse lacking the endogenous mouse
copper chaperone with a mouse harbouring mutant SOD1
transgenes did not alter the severity or survival of the double-
mutant mouse [60]. The decrease in copper loading did
correspond to a decrease in SOD1 dismutase activity, but did
not alter the disease course; from this, the authors concluded
that copper chemistry is not critical to mutant SOD1 toxicity. It
has been argued that the low levels of residual copper and
copper at alternative binding sites may still contribute to copper
mediated mutant SOD1 toxicity [99]. However, an ALS-like
phenotype is also observed if a quadruple mutant SOD1, where
each of the copper binding histidines are mutated to alanine, is
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maintains its toxicity despite the absence of copper at the active
site in mouse models of SOD1-ALS. This does not mean that
oxidative mechanisms involving copper chemistry are not
involved in ALS pathogenesis; rather, these models may by-
pass the necessity for oxidative damage where these mutations
mimic oxidatively modified histidines in their inability to bind
metals (see SOD1 misfolding, below).
8. Structural changes in mutant SOD1
Shortly after Rosen et al's discovery of mutations in SOD1
exon 2 or 4 can cause fALS [1], Deng et al. found additional
mutations in SOD1 exons 1, 2, 4 and 5 and carried out analysis of
what effect these mutations might have on SOD1 structure
[101,102,103]. The mutations they found clustered at the dimer
interface; these mutations were thought to disrupt the dimer,
disrupt the folding of the beta-barrel, or both. Mutant SOD1s
isolated from these patients showed reduced SOD1 activity in
red blood cells. Tainer et al. [17] point out that only 5 non-
glycine residues in the wild-type SOD1 structure fall outside the
allowed areas in the Ramachandran plot. The three most
common mutant SOD1 expressing mice are G93A, G37R and
G85R. Each of these residues falls outside the allowed area,
forcing conformational adjustments in the vicinity of the
mutated residues (Fig. 5). Destabilization caused by altering
these glycine residues may be a common feature of these mutant
SOD1s. Mutation of Gly 93 to various amino acids destabilized
SOD1 by levels corresponding to their preference for this
conformation [53]. The A4V SOD1 mutation is the most
common found in fALS patients. Comparison of the A4V and
wild-type SOD1 structures shows that there is only a 0.5 Å rmsd
when considering both the backbone and side chains [104]. This
is quite small when compared to a 1.71 Å rmsd between theFig. 5. SOD1 glycine mutations expressed in commonly used mouse models of ALS
torsional angles of SOD1 residues. The commonly used mouse models are circled—G
location of the common glycine mutants. G93 (green), G37 (pink), G85 (red).structures of oxidized (pdb code: 1SPD) and reduced (pdb code:
1C9V [105]) human SOD1. Local packing disruptions are
observed in the region of the A4V mutation because of the
inclusion of two extra methyl groups; however, it is unclear
whether this is sufficient to cause the large difference in
stabilities towards guanidine–HCl denaturation [104]. The
structure of the H46R SOD1 mutant, which is a zinc binding
ligand, shows that the histidine is replaced by a water ligand
[106]. The Asp124 ‘secondary bridge’ which is important for
stabilization of the active site with hydrogen bonds is also
disrupted in this mutant. The zinc-deficient mutant SOD1 shows
loss of structure in both the metal binding loop and the
electrostatic loop, but 20% zinc occupancy leads to complete
restoration of loop integrity [107]. This loss of structure also
allows for edge-strand interactions and leads to crystallization of
H46R, S134N and H43R mutants in arrays resembling fibrous
aggregates [106,108,109]. The new crystallographic interface
between SOD1 subunits observed in these crystal structures is
comparable to that of the native dimer interface [108].
9. Alterations in biochemical properties of mutant SOD1
Since there are minimal changes in the crystal structure of
fully metallated mutant SOD1 and the role of aberrant copper
redox chemistry is unclear, other biochemical properties of
mutant SOD1 must be involved in the pathogenesis of SOD1-
ALS. Mutant SOD1s are less thermostable than the wild-type
protein by 1–6 °C; interestingly, this was independent of the
metallation of the protein as the metallation seemed to confer
equal stability to wild-type and mutant SOD1s (approximately
14 °C for the first metallation and 22 °C relative to the apo- for
the second) [110]. Mutant SOD1s that cannot bind metals melt
at temperatures 4–12 °C lower than wild-type apo-SOD1 (c.f.
1–6 °C for mutants that can bind metals) [110]. When unfoldingfall outside the low energy areas. (A) Ramachandran plot showing the backbone
93 (green), G37 (pink), G85 (red). (B) Structure of a SOD1 subunit showing the
Fig. 6. Plausible free energy profile of oxidation induced SOD1 aggregation
(adapted from [122]). Mutant SOD1 is less stable than wild-type SOD1[53];
upon oxidation this populates a zinc-deficient state and a monomeric
intermediate prior to aggregation. Since oxidation causes conversion of histidine
to oxo-histidine, this disrupts metal binding capacity and the zinc-deficient
intermediate precedes the monomeric intermediate. The activation barrier for
conversion from SOD1 monomers to zinc-deficient aggregates is shown as
being small because zinc-deficient SOD1 aggregates spontaneously at 37 °C
[121] and oxidized SOD1 is more unstable to thermal denaturation than the
native form [122]. Aggregates produced from in vitro oxidation of holo-SOD1
are also zinc-deficient (unpublished data). Briefly, holo SOD1 is oxidized as in
Rakhit et al. [122], and the resultant aggregates are pelleted, washed three times
with ddH2O repeatedly before the final pellet is dissolved in 6 M HCl. The last
wash contained very low concentrations of copper and zinc. The protein and
metal contents of the pellet were determined by amino acid analysis and
graphite-furnace atomic absorbance spectroscopy, respectively.
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unfolds more easily than wild-type SOD1, but this effect is
more pronounced in apo-SOD1 than in the holo-protein. This
prompted Lindberg et al. to conclude that destabilization of apo-
SOD1 is common to fALS associated mutants [111]. However,
the apo-forms of some metal binding region mutant SOD1s
have higher melting temperatures than even wild-type SOD1.
These mutant apo-SOD1s also show similar H/D exchange
characteristics to that of wild-type apo-SOD1[112].
FALS-associated mutations are also thought to alter the metal
binding affinities of mutant SOD1. Mutations scattered across
SOD1 can alter the zinc binding geometry. This change allows for
greater flexibility in the active site, allowing faster reduction of Cu
(II) to Cu (I) by ascorbate. Mutant SOD1s were reduced at rates
comparable to zinc-deficient SOD1 [113]. The metal binding
affinities of SOD1 are so high that they are difficult to measure
directly. Instead, they are calculated by comparing the metal
release rates under mildly denaturing conditions and competition
for these metals with chelators of known binding affinity [92].
Using this methodology, Crow et al. calculated the dissociation
constants of zinc and copper in wild-type SOD1 to be
4.2×10−14 M and 6.0×10−18 M, respectively. Mutant SOD1s
had weaker zinc and copper binding affinities; however, the
difference in zinc binding was approximately 20–30 fold, where-
as the difference in copper binding was only 1–2 fold. Zinc
deficient SOD1 also catalyzed the formation of nitrotyrosine
faster than holo-SOD1 (mutant or wild-type) [92]. Recombinant
mutant SOD1s isolated from insect cells also showed decreased
metallation compared to wild-type SOD1. This corresponded
with a decreased catalytic rate of some of these mutant SOD1s in
pulse radiolysis experiments [114]. Zinc-deficient SOD1 activity
is 10× slower than that of holo-SOD1 at pH 8.0[115]. Alterations
in the metal binding geometry also causes a loss of metal binding
specificity in fALS-mutant SOD1s [115].
10. SOD1 misfolding
Before examining the case for SOD1 misfolding in ALS, it is
useful to begin with our definition of ‘misfolding’. We call a
protein ‘folded’ if it has regular structure, usually including
elements of secondary structure. Proteins in their native state are
often folded, but not always so [116]. A protein is ‘unfolded’ if
it is soluble and does not have any regular structure. We define
‘misfolding’ as a substantial alteration or re-organization of the
native protein structure.
The neuropathological evidence for SOD1 misfolding in
ALS is reviewed elsewhere (e.g., [117]). Briefly, inclusion
bodies are observed in almost all forms of ALS, both sporadic
and familial. These fall into three main categories: skein-like,
Bunina bodies, and hyaline. Skein-like inclusions are found in
nearly all ALS cases, and stain heavily with ubiquitin antibodies
and are occasionally positive for Dorfin, a ubiquitin E3 ligase
[117]. Bunina bodies are small eosinophilic inclusions (they are
positively charged) in motor and occasionally other neurons.
Hyaline inclusions are ‘glassy’ when stained and are large,
containing neurofilaments. Strong SOD1 staining, suggestive of
SOD1 aggregation, of hyaline inclusions is seen in most casesof human ALS carrying the SOD1 mutation and in mouse
models of SOD1-ALS [117–120]. In conjunction with evidence
from other neurological disorders where protein aggregation
and misfolding is thought to play a role, these hyaline inclusion/
aggregates are taken as the primary neuropathological evidence
for SOD1 misfolding in ALS. With the finding that mutant
SOD1 can cause an ALS-phenotype independent of copper
loading into the active site reducing the strength of the pro-
oxidation hypothesis of SOD1-ALS [60,100], a mechanism
involving SOD1 misfolding is coming to the forefront.
We aimed to reconcile these findings by suggesting that the
two leading hypotheses regarding mutant SOD1 toxicity,
increased oxidative stress and SOD1 misfolding, are causally
linked [121]. We hypothesize that SOD1 misfolding requires
and is a result of oxidation of SOD1 itself. SOD1 is an
exceptionally stable protein, the holo-protein having a melting
temperature of ∼95 °C [122]. Oxidation with hydrogen
peroxide causes metal release and inactivation [84]. We have
also shown that physiological metal catalyzed oxidation causes
destabilization and aggregation of SOD1[122]. Oxidized SOD1
is also found in a mouse model of ALS [123]. A number of
factors contribute to the selective vulnerability of SOD1 within
motor neurons to oxidative modification. SOD1 is present at
high concentration in motor neurons [68], and its normal
enzymatic function exposes it to high levels of oxidative stress,
predisposing it compared to other proteins to oxidative damage.
It also has a long life-time in motor neurons because of slow
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[121]. Decreasing SOD1 activity by limiting or eliminating
copper insertion may allow for greater damage to SOD1 itself,
thereby causing irreversible modification to histidine residues
that prevent it from binding to metals and properly folding. If
histidines are replaced with other residues, this mimics
oxidation of histidine by also impeding proper metallation.
Mutant SOD1s displayed greater aggregation propensity than
wild-type holo-SOD1 when treated with a relatively mild
oxidation system of copper and ascorbic acid. The most aggre-
gation prone species is zinc-deficient SOD1. Moreover,
aggregates produced from oxidation of holo-SOD1 were zinc-
deficient (Fig. 6). The aggregation propensity was proportional
to the extent of partially unfolding [121]. We refer to this species
as ‘misfolded’ because SOD1 is normally soluble and because
the circular dichroism spectrum shows a large change upon
aggregation. Other, non-physiological denaturational stresses,
such as heating in the presence of 30% TFE [124,125], also
showed that mutant SOD1s have an increased aggregation
propensity over the wild-type. Aggregation of SOD1 can also be
induced to misfold in vitro by heating at denaturing pH (pH 3.5)
[109,125] or by treating with the relatively strong oxidizing
combination of copper and hydrogen peroxide [126]. Molecular
dynamics simulations of SOD1 peptides derived from SOD1
find that N- and C-termini, as well as two beta-strands and two
loops are especially aggregation prone [127].
Whether the final protein aggregates are themselves toxic, or
whether some soluble precursor is the major toxic species is a
hotly debated subject. There have been conflicting reports
regarding the toxicity of SOD1 aggregates [128,129]. In order to
investigate whether protein-misfolding intermediates may play a
role in ALS pathogenesis, we looked for intermediates in our in
vitro model system [121,122]. Using dynamic light scattering
and analytical ultracentrifugation, we found that monomeric
SOD1 is a misfolding intermediate [122] (Fig. 6). The sugges-
tion of monomeric SOD1 formation in mutant SOD1 prepara-
tions at 70–80°C was then observed using X-ray scattering data
[130]. Monomeric SOD1 has since been identified as the
aggregation prone species in protein folding studies [125,131]
and in a detailed analysis of the SOD1misfolding pathway at pH
3.5 [125]. We are currently examining whether the monomeric
SOD1 intermediate observed in vitro exists in vivo [132].
11. Therapies targeting SOD1 misfolding
If misfolding is the cause of SOD1-ALS pathogenesis, a
hypothesis driven approach to drug design might be to find
drugs that stabilize the SOD1 dimer and prevent it from
misfolding. A similar approach has been applied in the case of
TTR amyloidoses [133]. Transthyretin (TTR, also called
prealbumin) is a tetrameric protein that is implicated in familial
amyloid polyneuropathy (FAP) [134]. It also dissociates to
monomers prior to aggregation [135]. Treatment with dibenzo-
furans selectively stabilizes the TTR tetramer [136]. Introduc-
tion of a second cysteine residue at the dimer interface was
thought to stabilize the SOD1 dimer by introducing an
intermolecular disulfide bond [137], but structural evidencefor this disulfide bond has not been reported. This mutant
appeared to prevent the loss due to aggregation of A4V SOD1
in a gel-filtration experiment in vitro, but failed to protect
against toxicity in a chick embryo [138]. Oxidation of SOD1
Cys 111 to cysteic acid also stabilizes SOD1 to unfolding and
aggregation [139]. If a small molecule can mimic this effect, it
may have therapeutic benefit. In a novel approach, Ray et al.
used computational design to find small molecules that bind to
and stabilize dimeric SOD1, but whether they are effective in
cell or animal models, or ultimately the clinic, remains to be
seen [140].
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